Back to Research

Organization profile

Novigenix

Novigenix is a Swiss precision medicine company that specializes in AI-powered liquid biopsy solutions to decode the human immune response for early cancer detection and therapy optimization. The company’s LITOSeek platform integrates immuno-transcriptomic profiling with genomic data to provide biopharma partners and oncologists with predictive insights into patient treatment response and toxicity risk.

Epalinges, SwitzerlandFounded 2012

Overview

1. Executive Summary (Confidence: High)

Novigenix is a leader in "Immune Intelligence," recently completing a strategic spin-out in 2026 to separate its colorectal cancer (CRC) screening business from its biopharma-focused AI platform.[30] The new entity, Novigenix AI, exclusively commercializes the LITOSeek platform, which analyzes whole-blood mRNA to predict therapy response and adverse event risks for checkpoint inhibitors and other immunotherapies.[30] Backed by an ISO 13485-certified analytics platform and €1.8 million in EU funding from the BRECISE consortium, Novigenix is industrializing its AI solutions for prostate and bladder cancers.[9] By shifting oncology from reactive to predictive, Novigenix provides a longitudinal view of patient immune status that traditional tissue biopsies cannot offer.[31]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.